Previous reports have shown that AURKA inhibition can inhibit proliferation of leukemic, Ewing, multiple myeloma, neuroblastoma and rhabdomyosarcoma cell lines (25, 41). conform to the characteristics appropriate for their morphological authentication (29). MLN8237 (Millennium Pharmaceuticals Inc., MA) stock answer (5.0mM) was prepared in 0.6% dimethy sulfoxide or DMSO (D4540) and diluted in cell culture press for the studies. For the studies, MLN8237 was formulated in 2-hydroxypropyl--cyclodextrin and sodium bicarbonate relating to manufacturer recommendations (Millennium Pharmaceuticals Inc.). Cisplatin (APP Pharmaceuticals, LLC., IL) stock answer (3.3mM) prepared in sterile water was provided by TVC Outpatient Pharmacy, Vanderbilt University or college Medical Center. Clonogenic cell survival assay FLO-1, OE19 and OE33 cells were seeded at 5000 cells/well inside a six well plate for 24hr and consequently treated with the MLN8237 (0.5M) and/or CDDP…